Megan Crichton
A5102736017- Cystic Fibrosis Research Advances
- Neonatal Respiratory Health Research
- Pediatric health and respiratory diseases
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Tracheal and airway disorders
- Respiratory viral infections research
- Dysphagia Assessment and Management
- Asthma and respiratory diseases
- Childhood Cancer Survivors' Quality of Life
- Respiratory and Cough-Related Research
- Respiratory Support and Mechanisms
- Esophageal and GI Pathology
- Inhalation and Respiratory Drug Delivery
- COVID-19 Clinical Research Studies
- Inflammatory Biomarkers in Disease Prognosis
- Long-Term Effects of COVID-19
- Forensic Toxicology and Drug Analysis
- Congenital Diaphragmatic Hernia Studies
- Gut microbiota and health
- Mycobacterium research and diagnosis
- SARS-CoV-2 and COVID-19 Research
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Infant Nutrition and Health
- Medical Imaging and Pathology Studies
- Delphi Technique in Research
University of Dundee
2016-2025
Ninewells Hospital
2015-2024
Dundee and Angus College
2020-2023
BackgroundNeutrophil extracellular traps (NETs) have been observed in the airway patients with chronic obstructive pulmonary disease (COPD), but their clinical and pathophysiologic implications not defined.ObjectiveWe sought to determine whether NETs are associated severity COPD how they microbiota composition neutrophil function.MethodsNET protein complexes (DNA-elastase histone-elastase complexes), cell-free DNA, biomarkers were quantified soluble sputum serum from during periods of...
Hospitalised patients with coronavirus disease 2019 (COVID-19) as a result of SARS-CoV-2 infection have high mortality rate and frequently require noninvasive respiratory support or invasive ventilation. Optimising standardising management through evidence-based guidelines may improve quality care therefore patient outcomes.A task force from the European Respiratory Society endorsed by Chinese Thoracic identified priority interventions (pharmacological non-pharmacological) for initial...
Bronchiectasis is a common but neglected chronic lung disease. Most epidemiological data are limited to cohorts from Europe and the USA, with few low-income middle-income countries. We therefore aimed describe characteristics, severity of disease, microbiology, treatment patients bronchiectasis in India.The Indian registry multicentre, prospective, observational cohort study. Adult (≥18 years) CT-confirmed were enrolled 31 centres across India. Patients due cystic fibrosis or traction...
Bronchiectasis is one of the most neglected diseases in respiratory medicine. There are no approved therapies and few large-scale, representative epidemiological studies. The EMBARC (European Multicentre Audit Research Collaboration) registry a prospective, pan-European observational study patients with bronchiectasis. inclusion criterion primary clinical diagnosis bronchiectasis consisting of: 1) history consistent bronchiectasis; 2) computed tomography demonstrating Core exclusion criteria...
Bronchiectasis is a heterogeneous, neglected disease with few multicentre studies exploring the causes, severity, microbiology, and treatment of across Europe. This aim this study was to describe clinical characteristics bronchiectasis compare between different European countries.
COPD and bronchiectasis are commonly reported together. Studies report varying impacts of co-diagnosis on outcomes, which may be related to different definitions disease used across studies.
Background Identifying risk factors for poor outcomes can help with stratification and targeting of treatment. Risk mortality exacerbations have been identified in bronchiectasis but almost exclusively studied European North American populations. This study investigated the outcome a large population patients enrolled India. Methods The Multicentre Bronchiectasis Audit Research Collaboration (EMBARC) Respiratory Network India (EMBARC-India) registry is prospective observational adults...
Background International guidelines recommend airway clearance management as one of the important pillars bronchiectasis treatment. However, extent to which is used for people with in Europe unclear. The aim study was identify use patients across different countries and factors influencing use. Methods This a prospective observational using data from European Multicentre Bronchiectasis Audit Research Collaboration (EMBARC) Registry between January 2015 April 2022. Prespecified options were...
Background A validated 4-point sputum colour chart can be used to objectively evaluate the levels of airway inflammation in bronchiectasis patients. In European Bronchiectasis Registry (EMBARC), we tested whether would associated with disease severity and clinical outcomes. Methods We a prospective, observational registry adults conducted 31 countries. Patients who did not produce spontaneous were excluded from analysis. The Murray was at baseline follow-up visits. Key outcomes frequency...
Asthma is commonly reported in patients with a diagnosis of bronchiectasis.
Identifying patients with COPD at increased risk of poor outcomes is challenging due to disease heterogeneity. Potential biomarkers need be readily available in real-life clinical practice. Blood eosinophil counts are widely studied but few studies have examined the prognostic value blood neutrophil (BNC).In a large population-based registry East Scotland (TARDIS: Tayside Allergic and Respiratory Disease Information System), BNC were compared measures severity mortality for up 15 years...
infection is associated with worse outcomes in bronchiectasis. Impaired neutrophil antimicrobial responses contribute to bacterial persistence. Gremubamab a bivalent, bispecific monoclonal antibody targeting Psl exopolysaccharide and the type 3 secretion system component PcrV.
Background Recent randomised clinical trials in bronchiectasis have failed to reach their primary end-points, suggesting a need reassess how we measure treatment response. Exacerbations, quality of life (QoL) and lung function are the most common end-points evaluated trials. We aimed determine relationship between responses terms reduced exacerbations, improved symptoms bronchiectasis. Methods response three that mucoactive therapy (inhaled mannitol), an oral anti-inflammatory/antibiotic...
Chest computed tomography (CT) scans are essential to diagnose and monitor bronchiectasis (BE). To date, few quantitative data available about the nature extent of structural lung abnormalities (SLAs) on CT patients with BE.
Phenazepam is a benzodiazepine that predominantly used clinically in the former Soviet states but being abused throughout wider world. This study reports tissue distribution and concentration of both phenazepam 3-hydroxyphenazepam 29 cases quantitated by liquid chromatography-tandem mass spectrometry (LC-MS/MS) variety post-mortem fluids (subclavian blood, femoral cardiac urine, vitreous humour) tissues (thalamus, liver psoas muscle). In 27 cases, cause death was not directly related to...
Bronchiectasis is a heterogeneous disease which affects quality of life. Measuring symptoms and life has proved challenging research limited by extrapolation questionnaires treatments from other diseases. The objective this study was to identify the major contributors in bronchiectasis evaluate existing health related bronchiectasis. Eight adults with participated one semi-structured interviews. These were recorded transcribed verbatim. Thematic analysis used core themes relevant burden...
Introduction Inhaled antibiotics may improve symptom scores, but it is not known which specific symptoms with therapy. Item-level analysis of questionnaire data allow us to identify respond best treatment. Methods Post hoc the AIR-BX1 studies and two trials inhaled aztreonam versus placebo in bronchiectasis. Individual items from quality life bronchiectasis (QOL-B) respiratory scale, were extracted as representing severity nine distinct symptoms. Generalised linear models used evaluate...